Incyte sank -2.9% this afternoon, compared to the S&P 500's day change of -1.0%. Today's losers may turn out to be tomorrow's winners, so be sure to check the stock's fundamentals before making an investment decision:
-
Incyte has logged a -6.7% 52 week change, compared to -7.0% for the S&P 500
-
INCY has an average analyst rating of buy and is -17.53% away from its mean target price of $88.94 per share
-
Its trailing earnings per share (EPS) is $1.56, which brings its trailing Price to Earnings (P/E) ratio to 47.0. The Health Care sector's average P/E ratio is 24.45
-
The company's forward earnings per share (EPS) is $4.98 and its forward P/E ratio is 14.7
-
The company has a Price to Book (P/B) ratio of 3.7 in contrast to the Health Care sector's average P/B ratio is 4.16
-
The current ratio is currently 3.5, which consists in its liquid assets divided by any liabilities due within in the next 12 months
-
INCY has reported YOY quarterly earnings growth of -95.2% and gross profit margins of 0.5%
-
The company's free cash flow for the last fiscal year was $892,108,000.00 and the average free cash flow growth rate is 9.0%
-
Incyte's revenues have an average growth rate of 12.0% with operating expenses growing at 12.5%. The company's current operating margins stand at 17.4%